Myasthenia gravis, autoimmune acquired (Q88653): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (6 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
A miastenia gravis adquirida é um transtorno autoimune da junção neuromuscular caracterizado por fraqueza muscular flutuante que muitas vezes afeta prefenrencialmente grupos musculares específicos. O resultado fisiopatológico é a disfunção da placa muscular e consequente fraqueza fatigável. Os subtipos são amplamente classificados como: miastenia gravis de início precoce (<50 anos); miastenia gravis de início tardio (> 50 anos); miastenia gravis associada a timoma; miastenia gravis com anticorpos anti-receptor tirosina quinase específico do músculo; miastenia gravis ocular; miastenia gravis sem anticorpos detectáveis. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1205670816 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:ID_1205670816 | |||||||||||||||
| Property / CURIE: CID11:ID_1205670816 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-ID_1205670816 | |||||||||||||||
| Property / Canary Token: dki-india-ID_1205670816 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 14:59, 15 August 2026
Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_1205670816 |
||
| English | Myasthenia gravis, autoimmune acquired |
Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies. |
Statements
CID11:ID_1205670816
0 references
dki-india-ID_1205670816
0 references
Concluído
0 references
13 August 2026
0 references
